$DCTH
Delcath Systems Inc

2016 Q2 Form 10-Q Financial Statement

#000156459016024344 Filed on August 15, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2015 Q2
Revenue $511.0K $466.0K
YoY Change 9.66% 85.66%
Cost Of Revenue $150.0K $137.0K
YoY Change 9.49% 107.58%
Gross Profit $361.0K $329.0K
YoY Change 9.73% 77.84%
Gross Profit Margin 70.65% 70.6%
Selling, General & Admin $2.287M $2.502M
YoY Change -8.59% -45.57%
% of Gross Profit 633.52% 760.49%
Research & Development $1.945M $1.450M
YoY Change 34.14% -2.82%
% of Gross Profit 538.78% 440.73%
Depreciation & Amortization $100.0K $200.0K
YoY Change -50.0% -33.33%
% of Gross Profit 27.7% 60.79%
Operating Expenses $4.232M $3.952M
YoY Change 7.09% -35.1%
Operating Profit -$3.871M -$3.623M
YoY Change 6.85% -38.63%
Interest Expense -$1.180M -$50.00K
YoY Change 2260.0% -103.85%
% of Operating Profit
Other Income/Expense, Net -$1.615M -$28.00K
YoY Change 5667.86% -500.0%
Pretax Income -$6.670M -$3.700M
YoY Change 80.27% -19.57%
Income Tax
% Of Pretax Income
Net Earnings -$6.667M -$3.699M
YoY Change 80.24% -19.59%
Net Earnings / Revenue -1304.7% -793.78%
Basic Earnings Per Share -$1.544K -$0.30
Diluted Earnings Per Share -$4.41 -$0.30
COMMON SHARES
Basic Shares Outstanding 1.511M 12.24M
Diluted Shares Outstanding 1.511M 12.24M

Balance Sheet

Concept 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.480M $14.05M
YoY Change -46.76% -48.5%
Cash & Equivalents $1.818M $14.05M
Short-Term Investments
Other Short-Term Assets $18.41M $1.100M
YoY Change 1573.64% 596.2%
Inventory $746.0K $280.0K
Prepaid Expenses
Receivables $363.0K $460.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $27.00M $15.89M
YoY Change 69.92% -45.04%
LONG-TERM ASSETS
Property, Plant & Equipment $1.062M $1.500M
YoY Change -29.2% -38.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $13.33M
YoY Change
Total Long-Term Assets $14.39M $1.499M
YoY Change 859.84% -38.06%
TOTAL ASSETS
Total Short-Term Assets $27.00M $15.89M
Total Long-Term Assets $14.39M $1.499M
Total Assets $41.39M $17.39M
YoY Change 138.01% -44.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $439.0K $528.0K
YoY Change -16.86% 120.0%
Accrued Expenses $2.035M $2.060M
YoY Change -1.21% -45.36%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $33.66M $3.349M
YoY Change 904.93% -37.98%
LONG-TERM LIABILITIES
Long-Term Debt $1.570M $0.00
YoY Change
Other Long-Term Liabilities $716.0K $929.0K
YoY Change -22.93% 23.87%
Total Long-Term Liabilities $716.0K $929.0K
YoY Change -22.93% 23.87%
TOTAL LIABILITIES
Total Short-Term Liabilities $33.66M $3.349M
Total Long-Term Liabilities $716.0K $929.0K
Total Liabilities $35.96M $4.278M
YoY Change 740.53% -30.44%
SHAREHOLDERS EQUITY
Retained Earnings -$269.7M -$253.7M
YoY Change 6.31%
Common Stock $15.00K $130.0K
YoY Change -88.46% 36.84%
Preferred Stock
YoY Change
Treasury Stock (at cost) $51.00K $51.00K
YoY Change 0.0% 0.0%
Treasury Stock Shares $110.00 $1.757K
Shareholders Equity $5.430M $13.11M
YoY Change
Total Liabilities & Shareholders Equity $41.39M $17.39M
YoY Change 138.01% -44.5%

Cashflow Statement

Concept 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income -$6.667M -$3.699M
YoY Change 80.24% -19.59%
Depreciation, Depletion And Amortization $100.0K $200.0K
YoY Change -50.0% -33.33%
Cash From Operating Activities -$3.150M -$4.550M
YoY Change -30.77% 13.75%
INVESTING ACTIVITIES
Capital Expenditures -$80.00K -$40.00K
YoY Change 100.0%
Acquisitions
YoY Change
Other Investing Activities -$1.060M $0.00
YoY Change -100.0%
Cash From Investing Activities -$1.140M -$40.00K
YoY Change 2750.0% -300.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.260M 180.0K
YoY Change 1155.56% 800.0%
NET CHANGE
Cash From Operating Activities -3.150M -4.550M
Cash From Investing Activities -1.140M -40.00K
Cash From Financing Activities 2.260M 180.0K
Net Change In Cash -2.030M -4.410M
YoY Change -53.97% 11.36%
FREE CASH FLOW
Cash From Operating Activities -$3.150M -$4.550M
Capital Expenditures -$80.00K -$40.00K
Free Cash Flow -$3.070M -$4.510M
YoY Change -31.93% 12.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0
CY2015Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0
CY2016Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
31181000
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
33655000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
14601000
CY2016Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
17162000
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
0
CY2016Q2 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
226000
CY2015Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
0
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1062000
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
277000
CY2016Q2 us-gaap Inventory Net
InventoryNet
746000
CY2015Q4 us-gaap Inventory Net
InventoryNet
757000
CY2016Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1245000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
960000
CY2016Q2 us-gaap Assets Current
AssetsCurrent
27000000
CY2016Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
13100000
CY2016Q2 us-gaap Assets
Assets
41388000
CY2015Q4 us-gaap Assets
Assets
15733000
CY2016Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
439000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
284000
CY2016Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2035000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2243000
CY2016Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
1568000
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1615000
CY2016Q2 us-gaap Gross Profit
GrossProfit
361000
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1945000
CY2016Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2287000
CY2016Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
511000
CY2016Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1181000
us-gaap Operating Income Loss
OperatingIncomeLoss
-7333000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
14000
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
269863000
us-gaap Operating Income Loss
OperatingIncomeLoss
-7332000
CY2015Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
48000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1132000
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
0
CY2016Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
363000
CY2015Q2 us-gaap Cost Of Revenue
CostOfRevenue
137000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
820000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-261217000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1396348
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1360239
CY2015Q4 us-gaap Treasury Stock Value
TreasuryStockValue
51000
CY2015Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
110
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-8000
CY2015Q4 us-gaap Liabilities
Liabilities
7132000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
8601000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15733000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q2 us-gaap Cost Of Revenue
CostOfRevenue
150000
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
765072
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.72
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-9.96
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1510752
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
114000
us-gaap Restricted Stock Expense
RestrictedStockExpense
190000
us-gaap Depreciation
Depreciation
169000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-1000
dcth Interest Income Earned On Money Market And Operating Accounts
InterestIncomeEarnedOnMoneyMarketAndOperatingAccounts
2000
us-gaap Cost Of Revenue
CostOfRevenue
270000
CY2016Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q2 us-gaap Gross Profit
GrossProfit
329000
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
15000
CY2016Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
19000
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1541016
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0
CY2016Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
716000
CY2016Q2 us-gaap Liabilities
Liabilities
35958000
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18000
CY2016Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
275182000
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-269698000
CY2016Q2 us-gaap Treasury Stock Value
TreasuryStockValue
51000
CY2016Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-18000
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
5430000
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41388000
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2016Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
910000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1521906
CY2016Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
110
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
880000
us-gaap Gross Profit
GrossProfit
619000
us-gaap Net Income Loss
NetIncomeLoss
-8480000
us-gaap Net Income Loss
NetIncomeLoss
-7189000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4663000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5542000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1450000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2430000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
3952000
us-gaap Operating Expenses
OperatingExpenses
7972000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3623000
CY2015Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
466000
CY2015Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2502000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3289000
us-gaap Operating Expenses
OperatingExpenses
7952000
CY2015Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3785000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6312000
CY2015Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0
us-gaap Gross Profit
GrossProfit
640000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
us-gaap Cost Of Revenue
CostOfRevenue
261000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-491000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-161000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
4232000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3871000
CY2015Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
3785000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-491000
CY2016Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
31181000
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.41
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.84
CY2015Q2 us-gaap Depreciation
Depreciation
200000
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-28000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1638000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-6667000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-3699000
CY2016Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7196000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1483148
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
722036
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
135000
us-gaap Restricted Stock Expense
RestrictedStockExpense
68000
us-gaap Depreciation
Depreciation
363000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-2000
dcth Interest Income Earned On Money Market And Operating Accounts
InterestIncomeEarnedOnMoneyMarketAndOperatingAccounts
1000
dcth Deferred Revenues
DeferredRevenues
19000
dcth Deferred Revenues
DeferredRevenues
0
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1568000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-170000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
126000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
94000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
285000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-14000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-59000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-42000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1712000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-104000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-110000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6968000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8957000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
95000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
87000
us-gaap Increase In Restricted Cash
IncreaseInRestrictedCash
1062000
us-gaap Increase In Restricted Cash
IncreaseInRestrictedCash
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1157000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-85000
us-gaap Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
-29200000
us-gaap Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
0
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
31523000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
704000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
2656000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
3027000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2656000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-25000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-30000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5123000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6416000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20469000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14053000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
28132000
CY2013Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
81875
CY2013Q4 dcth Proceeds From Issuance Of Private Placement Gross
ProceedsFromIssuanceOfPrivatePlacementGross
7500000
CY2013Q4 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
6900000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
820000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
245000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
123000
us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<div> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;text-indent:4.54%;">Deferred Revenue</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue on the accompanying condensed consolidated balance sheets includes payment received for product sales to a distributor. When obligations or contingencies remain after the products are shipped, such as training and certifying the treatment centers, revenue is deferred until the obligations or contingencies are satisfied. The Company will recognize the revenue related to product sales when its obligations under the agreement have been satisfied. </p></div>
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On July 19, 2016, shareholders of the Company approved, through a shareholder vote, an amendment to the Company’s Amended and Restated Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split of Delcath’s common stock at a ratio within a range of one-for-ten (1:10) to one-for-twenty (1:20). The reverse stock split became effective on July 21, 2016 at which time Delcath’s common stock began trading on the NASDAQ Stock Exchange on a one-for-sixteen (1:16) split-adjusted basis. All owners of record as of the open of the NASDAQ market on July 21, 2016 received one issued and outstanding share of Delcath common stock in exchange for sixteen issued and outstanding shares of Delcath common stock.
dcth Effective Date Of Reverse Stock Split
EffectiveDateOfReverseStockSplit
2016-07-21
CY2016Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
339000
CY2015Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
360000
CY2016Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
240000
CY2015Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
251000
CY2016Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
167000
CY2015Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
146000
CY2016Q2 us-gaap Prepaid Insurance
PrepaidInsurance
278000
CY2015Q4 us-gaap Prepaid Insurance
PrepaidInsurance
625000
CY2016Q2 dcth Kits For Clinical Use
KitsForClinicalUse
261000
CY2015Q4 dcth Kits For Clinical Use
KitsForClinicalUse
162000
CY2016Q2 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
452000
CY2016Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
254000
CY2015Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
173000
CY2016Q2 dcth Maximum Percentage Of Prepaid Expenses And Other Current Assets
MaximumPercentageOfPrepaidExpensesAndOtherCurrentAssets
0.05
CY2015Q4 dcth Maximum Percentage Of Prepaid Expenses And Other Current Assets
MaximumPercentageOfPrepaidExpensesAndOtherCurrentAssets
0.05
CY2016Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4740000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4638000
CY2016Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3678000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3506000
CY2016Q2 us-gaap Depreciation
Depreciation
100000
CY2016Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
664000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
692000
CY2016Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
183000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
391000
CY2016Q2 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
214000
CY2015Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
220000
CY2016Q2 dcth Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
437000
CY2015Q4 dcth Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
219000
CY2016Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
537000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
721000
CY2016Q2 dcth Maximum Percentage Of Current Liabilities Accrued
MaximumPercentageOfCurrentLiabilitiesAccrued
0.05
CY2015Q4 dcth Maximum Percentage Of Current Liabilities Accrued
MaximumPercentageOfCurrentLiabilitiesAccrued
0.05
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
153750
CY2015Q1 dcth Proceeds From Issuance Of Private Placement Gross
ProceedsFromIssuanceOfPrivatePlacementGross
2600000
CY2015Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
2500000
CY2015Q3 us-gaap Partners Capital Account Units Sale Of Units
PartnersCapitalAccountUnitsSaleOfUnits
600000
CY2015Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
600000
CY2015Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6000000
dcth Number Of Inputs Used For Valuation Of Warrants
NumberOfInputsUsedForValuationOfWarrants
6
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7488515
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
192570

Files In Submission

Name View Source Status
0001564590-16-024344-index-headers.html Edgar Link pending
0001564590-16-024344-index.html Edgar Link pending
0001564590-16-024344.txt Edgar Link pending
0001564590-16-024344-xbrl.zip Edgar Link pending
dcth-10q_20160630.htm Edgar Link pending
dcth-20160630.xml Edgar Link completed
dcth-20160630.xsd Edgar Link pending
dcth-20160630_cal.xml Edgar Link unprocessable
dcth-20160630_def.xml Edgar Link unprocessable
dcth-20160630_lab.xml Edgar Link unprocessable
dcth-20160630_pre.xml Edgar Link unprocessable
dcth-ex311_9.htm Edgar Link pending
dcth-ex312_7.htm Edgar Link pending
dcth-ex321_6.htm Edgar Link pending
dcth-ex322_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending